CIP2A and neoplasm: Consistent with our findings, although lncRNA LINC00665 has been reported to exert a promoting effect on the progression of breast cancer [34, 35], its 52-aa peptide CIP2A-BP functions as an anti-tumor factor in TNBC via the PP2A/PI3K/AKT/NF-κB pathway by binding the oncogene CIP2A [14].